alecensa
roche registration gmbh - alectinib hidroklorid - karcinom, ne-malih stanica pluća - antineoplastična sredstva - alecensa kao monoterapija je indicirana za prvu liniju liječenja odraslih pacijenata s anaplastičnim limfomom kinazom (alk) - pozitivnim ne-malim stanicama raka pluća (nsclc). alecensa u monoterapiji namijenjen za liječenje odraslih bolesnika s alk‑pozitivan НМРЛ, prethodno liječenih crizotinib.
alecensa (▼) 150 mg/1 kapsula kapsula, tvrda
roche d.o.o.roche ltd. - alectinib - kapsula, tvrda - 150 mg/1 kapsula - 1 kapsula, tvrda sadrži: 150 mg alektiniba (u obliku alektinibhlorida)
lorviqua
pfizer europe ma eeig - lorlatinib - karcinom, ne-malih stanica pluća - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
lorviqua 25 mg/1 tableta filmom obložena tableta
pfizer bh d.o.o. sarajevo - lorlatinib - filmom obložena tableta - 25 mg/1 tableta - 1 filmom obložena tableta sadrži 25 mg lorlatiniba
lorviqua 100 mg/1 tableta filmom obložena tableta
pfizer bh d.o.o. sarajevo - lorlatinib - filmom obložena tableta - 100 mg/1 tableta - 1 filmom obložena tableta sadrži 100 mg lorlatiniba
lumeblue (previously known as methylthioninium chloride cosmo)
alfasigma s.p.a. - metiltioninijev klorid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.